XML 38 R29.htm IDEA: XBRL DOCUMENT v3.25.3
Segment Information
9 Months Ended
Sep. 30, 2025
Segment Information  
Segment Information

23.Segment Information

ASU No. 2023-07 Topic 280, “Segment Reporting” establishes standards for reporting information about operating segments on a basis consistent with the Company’s internal organization structure as well as information about services categories, business segments and major customers in financial statement. The Company manages its business in one reportable operating segment, which is primarily engaged in the manufacturing, marketing, and sales of its patented and FDA cleared product, QuantaFlo. In accordance with Topic 280, the Chief Executive Officer and President has been identified as the Company’s chief operating decision maker (“the CODM”), who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company. The CODM uses segment operating profit to allocate resources including employees, property and investments. The CODM also uses month-over-month expense variance analysis for cost control and for making decisions about allocating capital and personnel to the segment.

The following table breaks out the operations of the Company’s single reportable segment information.

Three months ended September 30, 

Nine months ended September 30, 

    

2025

    

2024

    

2025

    

2024

Revenue

$

7,491

$

13,512

$

24,543

$

43,881

Less:

Cost of revenue

580

1,075

2,106

3,342

Research and development (1)

1,106

1,165

3,642

3,695

Sales

913

1,439

2,804

4,460

Sales operations

754

697

2,281

2,260

General and administration

7,993

3,128

17,989

8,902

Litigation settlement expense

29,750

Depreciation and amortization

87

133

317

479

Other segment expenses (2)

1,448

810

4,200

3,352

Segment operating (loss) profit

$

(5,390)

$

5,065

$

(38,546)

$

17,391

Interest income (expense), net

(338)

168

(214)

1,699

Interest on 2030 Senior Notes

(1,237)

(3,312)

Impairment of investments

(1,135)

Change in fair value of notes

128

Change in fair value of digital assets

28,490

1,137

70,422

(3,918)

Change in fair value of Bitcoin collateral

1,471

1,471

Gain on conversion of notes receivable

803

803

Other corporate income (3)

4

5

7

8

Income before taxes

23,803

6,375

29,496

15,308

Income tax expense

6,901

766

10,364

3,615

Net income

$

16,902

$

5,609

$

19,132

$

11,693

1.Research and development expenses include clinical affairs and HITRUST.
2.Other segment expenses include marketing, customer education and business development.
3.Other corporate income represents unallocated income.